GC Biopharma Corp.

A006280

KR7006280002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
111,900 ^KRW	+0.72%		+2.57%	-10.84%

Mar. 20	GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	CI

GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 03:16 am EDT

GC Biopharma Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 0.0003 million compared to negative sales of KRW 0.00004 million a year ago. Net income was KRW 1,768.18 million compared to KRW 12,937.45 million a year ago. Basic earnings per share from continuing operations was KRW 155 compared to KRW 1,133 a year ago. Basic earnings per share was KRW 155 compared to KRW 1,133 a year ago.
For the six months, sales was KRW 0.00031 million compared to KRW 0.00023 million a year ago. Net loss was KRW 20,684.69 million compared to net income of KRW 19,327.07 million a year ago. Basic loss per share from continuing operations was KRW 1,812 compared to basic earnings per share from continuing operations of KRW 1,693 a year ago. Basic loss per share was KRW 1,812 compared to basic earnings per share of KRW 1,693 a year ago.

Latest news about GC Biopharma Corp.

GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	Dec. 17	CI
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea	Dec. 01	CI
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
GC Biopharma Applies for MFDS Approval	Nov. 05	CI
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases	23-10-12	CI
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Green Cross's Net Income Plunges in Q2	23-08-02	MT
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt	23-07-21	CI
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia	23-06-01	CI
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Green Cross Swings to Loss in Q1	23-05-02	MT
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	23-03-01	MT
GC Biopharma Receives WHO Pre-Qualification for BARYCELA	23-02-19	CI
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea	23-02-08	CI
Curevo, Inc. announced that it has received $22.000002 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, GC Biopharma Corp. and other investors	22-11-20	CI
Green Cross Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Curevo, Inc. announced that it expects to receive $26.000003 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, Green Cross Corporation	22-11-08	CI
Green Cross' Net Profit Falls 27% in Q3	22-11-01	MT
Green Cross Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Green Cross' Net Income Rises 3% in March Quarter	22-05-02	MT
GC Biopharma Concludes Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics	22-04-28	CI
GC Pharma has Changed its Name to GC Biopharma Corp	22-03-29	CI
GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'	22-02-27	CI
MedAdvisor Expands to New Zealand with Green Cross Health Deal	22-02-18	MT

Chart GC Biopharma Corp.

Duration

Period

More charts

Company Profile

Green Cross Corp is a Korea-based company that mainly engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The Company also provides genome analysis services.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for GC Biopharma Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

111,900 KRW

Average target price

144,667 KRW

Spread / Average Target

+29.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GC BIOPHARMA CORP.	-10.84%	928M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals